Comparing RapidArc Therapy for Liver Cancer
Author Information
Author(s): Kuo Yu-Cheng, Chiu Ying-Ming, Shih Wen-Pin, Yu Hsiao-Wei, Chen Chia-Wen, Wong Pei-Fong, Lin Wei-Chan, Hwang Jeng-Jong
Primary Institution: National Yang-Ming University
Hypothesis
To compare the RapidArc plan for primary hepatocellular carcinoma (HCC) with 3-D conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) plans using dosimetric analysis.
Conclusion
RapidArc provided favorable tumor coverage compared with IMRT or 3DCRT, but is not superior to IMRT in terms of liver protection.
Supporting Evidence
- RapidArc achieved significantly better CI and V107% values than IMRT or 3DCRT.
- The MUs were significantly lower for RapidArc and 3DCRT than for IMRT.
- IMRT achieved a significantly lower Dmean of the normal liver than did 3DCRT or RapidArc.
- 3DCRT had higher V40 Gy and V30 Gy values for the normal liver than did RapidArc or IMRT.
- The NTCP did not differ significantly between RapidArc and IMRT.
Takeaway
This study looked at different ways to treat liver cancer with radiation. RapidArc was good for targeting the tumor, but it didn't protect the liver better than another method called IMRT.
Methodology
Nine patients with unresectable HCC were enrolled, and dosimetric values for RapidArc, IMRT, and 3DCRT were calculated for total doses of 45~50.4 Gy using 1.8 Gy/day.
Limitations
Small patient numbers, relatively coarse 5 mm-slice thickness, and lack of respiratory control or abdominal compression.
Participant Demographics
All patients were male with a median age of 57 years (range, 38-81 years); 5 had Child-Pugh score A cirrhosis and 4 had Child-Pugh score B cirrhosis.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website